We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Two Simple Serum Biomarkers Differentiate Lymphoma from Glioma

By LabMedica International staff writers
Posted on 22 Apr 2022
Print article
Image: Micrograph of brain tissue with glioma enlargement and disease histology (Photo courtesy of 123rf.com)
Image: Micrograph of brain tissue with glioma enlargement and disease histology (Photo courtesy of 123rf.com)

A recent study found that two simple serum biomarkers, absolute lymphocyte count and prognostic nutritional index, which are easily derived from routine pre-treatment blood tests, have fair correlation and acceptable diagnostic accuracy for differentiating primary central nervous system lymphoma (PCNSL) from high-grade glioma (HGG) in patients with similar morphology on MRI.

A complex series of interactions take place between cancer and inflammation that are reflected by increased release of inflammatory biomarkers into the bloodstream. However, the utility of systemic inflammatory biomarkers as a means for the noninvasive differential diagnosis of PCNSL from HCC is generally lacking.

To repair this lack, investigators at the Homi Bhabha National Institute (Mumbai, India) and their colleagues carried out a study that involved calculating systemic inflammatory indices from pre-treatment complete blood counts and liver function tests and comparing them against histopathology as the reference standard among 42 patients with PCNSL and 16 with HGG.

Results revealed that the area under the receiver operating characteristics curve for absolute lymphocyte count and prognostic nutritional index in the diagnosis of PCNSL was 0.70 and 0.72 respectively, which suggested that these markers yielded fair and acceptable diagnostic accuracy.

The investigators said, "This exploratory first-of-a kind study assessed the utility of systemic inflammatory biomarkers derived from routine blood investigations in a cohort of patients with suspected PCNSL to differentiate them reliably from HGG with similar morphologic imaging."

The study was published in the April 4, 2022, online edition of the journal CNS Oncology.

Related Links:
Homi Bhabha National Institute 

Gold Supplier
Chromogenic Medium
CHROMagar Candida Plus
New
Molecular Diagnostic System
FlashDetect Flash48
New
3-Part Diff Hematology Analyzer
DLB3
New
3-DIFF Hematology Analyzer
MYTHIC 18

Print article

Channels

Clinical Chem.

view channel
Image: The analysis pipeline used to investigate associations between blood metabolites, later life brain imaging measures, and genetic risk for Alzheimer’s disease (Photo courtesy of University College London)

Lipid Measurements Show Potential as Alzheimer’s Disease Biomarkers

Brain changes accompanying ageing are varied and can include pathologies that lead to cognitive impairment, the commonest of which is Alzheimer’s disease (AD). Identifying blood-based signatures of brain... Read more

Molecular Diagnostics

view channel
Image: Researchers have identified 10 new genes linked with hearing loss (Photo courtesy of 123rf.com)

Newly Identified Genes May Help to Screen and Treat Individuals with Hearing Loss

A massive genome-wide association study (GWAS) identified 10 novel gene loci associated with hearing loss, which may aid in screening and treating the disorder. Hearing loss is one of the top contributors... Read more

Industry

view channel
Image: Sales of lateral flow assays in clinical testing are expected to register a CAGR of 5% through 2032 (Photo courtesy of Pexels)

Global Lateral Flow Assays Market to Surpass USD 11.5 Billion by 2032 Due to Evolving Applications

The global lateral flow assays market was valued at USD 7.2 billion in 2021 and is projected to register a CAGR of 4.7% during 2022-2032 to surpass USD 11.7 billion by the end of 2032, driven by the growing... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.